ESMO 2020 Updates on NSCLC: 1L Cemiplimab vs. Platinum-Doublet Chemo in Advanced Disease, Atezo + Bev for High PD-L1 Non-Sq Disease, 1L Nivo + Carboplatin/Paclitaxel/Bev for Advanced/Recurrent Non-Sq Disease

253 views
January 5, 2021
0 Comments
Login to view comments. Click here to Login